Pfizer Inc. (NYSE:PFE) has been working on its molecule Xeljanz for the management and treatment of ulcerative colitis. The drugmaker is due to present the clinical studies in the United European Gastroenterology Week (UEG Week 2016), October 15-19 in Vienna, Austria.
The molecule has shown comprehensive efficacy and safety profile in the Phase 3 Oral Clinical Trials in the patients suffering from ulcerative colitis. The drug belongs to Janus kinase (JAK) inhibitors class which is the latest one in the treatment of aforementioned disease. If approved, the molecule will be available in the oral formulation as it significantly reduces the inflammation occurred during the ulcerative colitis.
After its approval by the Food and Drug Administration (FDA) for the patients suffering from rheumatoid arthritis, the drug failed to generate the expected revenue as well as prescription, so Pfizer is working on the label expansion of the drug in order get traction in the revenue generation. According to the analysts’ expectations, the drug is thought to generate $3 billion annually, but failed to do so due to the presence of fierce competition in the RA therapeutic market.
In Europe, the drug is still facing problem due to its safety profile as well as it was failed to prove its efficacy and safety in the patients of psoriasis despite its approval as New Drug Application in October 2015.
The drug is already gained approval in 50 countries for the management and treatment of rheumatoid arthritis and it is increasing its therapeutic area slowly and steadily.
Ulcerative colitis belongs to a debilitating disease directly affecting the gastrointestinal system specially the immune system, colon or intestines. Due to the severe symptomatology of the disease such as abdominal pain, fever, weight loss and chronic, bloody diarrhea, the patient’s social life and family life has been disturbed to maximum degree.
Despite the aforementioned diseases, the drug is also proved its vitality in the alopecia. It works by inhibiting the role of the immune system on the hair follicle thus reducing the chances of alopecia.